Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Oct 28, 2019 7:00 AM - Oct 30, 2019 12:30 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 5 Track C: Oligonucleotide Degradation, Stability, and the Question of Terminal Sterilization

Learning Objective : At the conclusion of this session, participants should be able to:
  • Estimate the influence of terminal sterilization on the product quality of synthetic oligonucleotides


Daniel  DeCollibus, MS

Key Considerations in Terminal Sterilization Development of Oligonucleotides

Daniel DeCollibus, MS

Biogen, United States

Scientist I

Bianca  Matthee, PharmD, MPharm, MSc

Sterilizing Oligonucleotide-Containing Formulations

Bianca Matthee, PharmD, MPharm, MSc

ProQR Therapeutics, Netherlands

Vice President CMC

Jonathan  Burgos, PhD


Jonathan Burgos, PhD

CDER, FDA, United States

Lieutenant Commander, U.S. Public Health Service Commissioned Corps

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.